PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | B761170 | GENENTECH INC
Earliest legal licensure (12-year BPCIA floor)
The 12-year reference-product exclusivity is the non-carveable floor — the earliest FDA could license a biosimilar for any indication. Unverified estimate — derived from the earliest available approval record (Jun. 29, 2020), not an FDA-stated exclusivity date. Shown with lower confidence than a Purple Book value.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Jun. 29, 2032 | 5y 11mo remaining | 12-year RPE floor (non-carveable) |
| Full-label entry | Jun. 29, 2032 | 5y 11mo remaining | 12-year RPE floor |
Best-skinny equals full-label — no carveable orphan block runs past the licensure floor.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 11999801(composition)· AI-discovered, not Purple-Book-listed · relevance 70/100. This caps practical skinny-label entry; it does not move the licensure floor above.
27 formulation/compound (cap skinny entry) · 0 method-of-use (carveable — gate nothing) · 23 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 12371728 | Other | Jul. 24, 2045Active | Discovered |
| 12359001 | Other | Jul. 10, 2045Active | Discovered |
| 12269867 | Other | Apr. 3, 2045Active | Discovered |
| 12180279 | Other | Dec. 26, 2044Active | Discovered |
| 12173080 | Other | Dec. 19, 2044Active | Discovered |
| 12174184 | Other | Dec. 19, 2044Active | Discovered |
| 11999801 | Formulation/compound | May. 30, 2044Active | Discovered |
| 11987637 | Other | May. 16, 2044Active | Discovered |
| 11976127 | Other | May. 2, 2044Active | Discovered |
| 11905325 | Other | Feb. 15, 2044Active | Discovered |
| 11891434 | Formulation/compound | Feb. 1, 2044Active | Discovered |
| 11865177 | Formulation/compound | Jan. 4, 2044Active | Discovered |
| 11718678 | Formulation/compound | Aug. 3, 2043Active | Discovered |
| 11680110 | Other | Jun. 15, 2043Active | Discovered |
| 11634836 | Other | Apr. 20, 2043Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 188 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
The Trustees of the University of Pennsylvania v. Genentech, Inc. 2 patentstrastuzumab, pertuzumab | D. Del. | 2022-01-31 | Terminated 2025-03-14 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.